Book Value per Share: ChromaDex Corp. (NAGE)

Graphic logo of niagenbioscience.com (NAGE)

Chromadex Corp (NAGE) dominates the cellular metabolism segment thanks to robust intellectual property that prevents competitor dumping. The company's success is based on the protection of Tru Niagen rights, with margins standing at 1.05, while B2B contracts and DTC sales remain the key growth drivers. This daily price chart on GURU.Markets links these metrics to the brand's development vector within the longevity niche and the supply of NAD+ raw materials to global corporations.

ChromaDex (NAGE) - Accounting Value per Share from 03/20/2025 to 10/27/2026

Summary analytical data breakdowns for ChromaDex Corporation (NAGE)

- price and consensus price forecast:
Stock Price ChromaDex Corp|NAGE - Analyst Target Range
- market capitalization data:
Market Capitalization ChromaDex Corp.|NAGE - Total Enterprise Value
- book capitalization data:
Net Assets per Single Share ChromaDex|NAGE - Company Net Assets|Market Capitalization to Book Value Ratio niagenbioscience.com|NAGE - Company Assets
- debt and liquidity data:
Total Debt to Capital Chromadex Corp|NAGE - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital Chromadex Corp|NAGE - Company Total Debt Obligations|Debts to Book Capitalization ChromaDex Corp.
Analysis of all company metrics:ChromaDex - NAGE
Manufactured product of ChromaDex Corporation

Chromadex Corp (NAGE) focuses on biomedical research into cellular longevity and the creation of innovative nutraceuticals. The book value per share determines the portion of equity attributable to a single security upon full liquidation of the business. Analysis of the BVPS chart allows for an assessment of the real value of assets relative to market quotes. Growth in this indicator confirms the capitalization of R&D scientific potential. This metric characterizes the defensive qualities of the investment.

Competitors of Chromadex Corp (NAGE)

Book Value per Share ISRG|DHR - Book Value of One Share|Book Value per Share BDX|STE (steris.com) - Net Asset Value per Share|Net Assets per Single Share WST|Accounting Value per Share Baxter International Inc.|Masimo Personal Health - Book Value per Share|Net Asset Value per Share Stevanato Group Corp (STVN)|TFX - Book Value per Share|Equity per Share merit.com MMSI|Book Value per Share NVST (Envista)|ICUI - Net Assets per Share|XRAY (Dentsply) - Book Value per Share|LeMaitre Corp (LMAT) - Accounting Value per Share|ATRC (AtriCure, Inc.) - Book Value per Share|Book Value per Share STAA|Net Assets per Single Share ZimVie (ZIMV)|Net Assets per Single Share AngioDynamics Inc ANGO|Accounting Value per Share Cerus Corp|Accounting Value of a Share Teknova Inc TKNO|Book Value per Share MGRM (Monogram Technologies)|STSS: Net Assets per Share|Net Assets per Single Share infusystem.com|UTMD (Utah Medical Products Inc.) - Equity per Share|KRMD: Net Assets per Single Share|Net Assets per Share Nyxoah S.A (NYXH)|Accounting Value per Share Microbot Medical Inc.|Book Price of a Share PDEX (pro-dex.com)|Net Assets per Single Share Zentek|ELUT - Accounting Value of a Share|Milestone Scientific Corp - Accounting Value per Share|NXGL: Book Value per Share|RVP (retractable.com) - Net Assets per Single Share|harvardbioscience.com (HBIO) - Accounting Value per Share|Book Value per Share FEMY (Femasys)|Net Asset Value per Share MHUA|Net Assets per Single Share Predictive Oncology POAI|Equity per Share callanjmb.com CJMB|Accounting Value per Share Atrion Corporation (ATRI)|neurometrix.com - Book Price of a Share